Previous 10 | Next 10 |
LONDON and NEW YORK, Aug. 15, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (“DED”) to address the significant unmet need in this multi-billion-dollar market, today...
2023-08-01 10:26:25 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Nikola (NASDAQ: NKLA ) stock is rising higher on Tuesday after the company announced $16.3 million in new funding for its hydrogen refueling stations. This funding is a ...
2023-08-01 10:04:48 ET Gainers: Adamis Pharmaceuticals ( ADMP ) +71% . ABVC BioPharma ( ABVC ) +49% . EQRx ( EQRX ) +18% . Rhythm Pharmaceuticals ( RYTM ) +17% . Esperion Therapeutics ( ESPR ) +6% . Losers: TG Therapeu...
2023-08-01 08:38:44 ET TG Therapeutics ( TGTX ) -40% after Q2 earning release . ZoomInfo Technologies ( ZI ) -20% after Q2 earning release . Vision Marine Technologies ( VMAR ) -18% on direct registered offering of 0.49M shares at $4.05 . Ze...
2023-07-31 13:08:57 ET Gainers: Mallinckrodt ( MNK ) +42% . Fifth Wall Acquisition Corp. III ( FWAC ) +40% . Tupperware Brands Corporation ( TUP ) +40% . GoodRx Holdings ( GDRX ) +37% . Archer Aviation ( ACHR ) +36% . Steakho...
2023-07-31 08:19:22 ET Checkpoint Therapeutics ( CKPT ) -14% announces $10 Million registered direct offering priced at-the-market. Citius Pharmaceuticals ( CTXR ) -13% . BioNexus Gene Lab Corp. ( BGLC ) -13% . Blue Star Foods Corp. ( BSFC ) -...
2023-07-31 03:39:28 ET Ophthalmology-focused biopharmaceutical company OKYO Pharma ( OKYO ) stock price has rebounded ~19% after falling about 25% during after hours of trading on Friday, touching the lowest level of ~$1.50. The price movements took place after the company r...
LONDON and NEW YORK, July 31, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO) (“OKYO” or the “Company”), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (DED) to address the significant unmet need in t...
LONDON and NEW YORK, July 28, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO) (“OKYO” or the “Company”), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (DED) to address the significant unmet need in t...
2023-07-28 17:20:26 ET OKYO Pharma ( NASDAQ: OKYO-OLD ) said on Friday that Nasdaq had notified it that for the previous 30 consecutive business days, the market value of OKYO's ordinary shares had closed below the minimum $35M requirement. OKYO shares fell 6.4% in ex...
News, Short Squeeze, Breakout and More Instantly...
Phase 2 randomized, placebo-controlled trial in neuropathic corneal pain (NCP) patients planned to begin in Q3, 2024 OK-101 is believed to be the first IND clearance granted by FDA for a drug to begin clinical studies specifically to treat patients suffering with neuropathic corneal pain ...
Encouraging 68% improvement in responder rate results from patients who achieved both the conjunctival staining “sign” and ocular pain “symptom” endpoints from the 240 patient Phase 2 Dry Eye Disease (DED) trial Conjunctival staining and ocular pain represe...
--News Direct-- OKYO Pharma Ltd CEO Gary Jacobs joined Steve Darling from Proactive to share additional key findings from the Phase 2 clinical trial evaluating the safety and efficacy of OK-101 (0.05%) ophthalmic solution in patients with dry eye disease (DED). This trial involved 240 pat...